Skip to content
Open access

Context-dependent regulatory networks connect Alzheimer’s disease genetics to microglial inflammatory responses

Aug 2026 · bioRxiv · 0 citations · 2 references
Biology

Abstract

Inflammation is central to Alzheimer’s disease (AD) pathogenesis. Microglia, the resident innate immune cells of the brain, exhibit diverse inflammatory states and are enriched for AD-associated genetic variants within active cis-regulatory elements (CREs). However, the interplay among genetic variants, transcription factor (TF)–CRE– gene programs, and microglial responses across inflammatory and disease contexts remain poorly understood. Here, we develop context-dependent epigenomic networks (cEpiNets), integrating bulk and single-nucleus assay for transposase-accessible chromatin using sequencing (ATAC-seq) to reconstruct regulatory programs across inflammatory, genetic perturbation, and disease contexts. Leveraging TF footprinting and graph embedding, cEpiNets identifies shared and context-specific programs and predicts regulatory circuits in unseen biological contexts. In a SORL1-marked inflammatory microglial state that expands during AD progression, cEpiNets annotates AD risk variants at the SORL1 locus and identifies variants associated with cellular state abundance across donors. Cross-context analysis further identifies ZBTB14, whose inflammation-associated program connects AD risk variant–harboring CREs to target genes and widespread TF remodeling in AD. Donor-level ZBTB14 footprint activity is negatively associated with AD pathology, while combined IFNγ/TNFα stimulation represses ZBTB14 and activates a subset of inferred targets. Collectively, cEpiNets bridges genetic variation, regulatory programs, and disease-associated cellular phenotypes to facilitate mechanistic interpretation of complex disease genetics.

Read PDF

Similar papers

Open access Aug 2026

Peripheral blood microarray-based transcriptomic and epigenetic analyses identify immune, inflammation, and metabolic dysregulation in Alzheimer’s disease

Leveraging multi-omics to better understand the molecular signatures and pathways underlying Alzheimer’s disease (AD) pathogenesis is critical for early diagnosis and disease modifying interventions. We performed peripheral blood transcriptome (N = 669) and epigenome microarray analyses (N = 553) on non-Hispanic white...

Brendan A. Mitchell, I. Hausle, Sarah Smith et al. · 0 citations
#graph neural networks Open access Sep 2026

Personalized single-cell transcriptomics reveals molecular diversity in Alzheimer’s disease

Alzheimer’s disease (AD) is highly heterogeneous and driven by diverse molecular and cellular mechanisms. Functional genomics investigates these mechanisms from genetic variants to gene expression and regulation. We performed personalized functional genomics analysis on population-scale single-nucleus RNA-seq data, wit...

P. Chandrashekar, S. Alatkar, Noah Cohen Kalafut et al. · 1 citation
Open access Sep 2026

Integrative transcriptomic analysis reveals KLHL2 downregulation as a potential driver of microglial inflammation in Alzheimer’s disease via the WNK3/JNK/c-Jun axis

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by prominent neuroinflammation. Microglia, the resident immune cells of the central nervous system, play a key role in AD-associated neuroinflammation, yet the molecular mechanisms regulating their inflammatory activation remain incomple...

Yao Yang, Cong-Hui Dai, Zong-Tang Xu et al. · 0 citations
Open access Aug 2026

Plasticity of human microglia and brain perivascular macrophages in aging and Alzheimer’s disease

It is shown that a disease-associated microglial subtype, characterized by elevated GPNMB expression and enriched for polygenic AD risk, expands with AD pathology and shows increased phagocytic activity, and MITF is identified as an upstream regulator required to maintain this microglial state.

Donghoon Lee, James M. Vicari, Christian Porras et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.